B
70.40
-0.54 (-0.76%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | BridgeBio Pharma, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.1
| 分析师共识 | 4.0 |
| 内部交易活动 | -5.0 |
| 价格波动 | -1.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.10 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.97% |
| 机构持股比例 | 98.14% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Viking Global Investors Lp | 31 Dec 2025 | 14,393,934 |
| Kohlberg Kravis Roberts & Co. L.P. | 31 Dec 2025 | 13,260,971 |
| Brooklands Fund Management Ltd | 31 Dec 2025 | 2,750,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 125.00 (Evercore ISI Group, 77.56%) | 购买 |
| 中 | 96.50 (37.07%) | |
| 低 | 80.00 (Barclays, 13.64%) | 购买 |
| 平均值 | 96.38 (36.90%) | |
| 总计 | 8 购买 | |
| 平均价格@调整类型 | 71.13 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 10 Mar 2026 | 94.00 (33.52%) | 购买 | 74.32 |
| Evercore ISI Group | 25 Feb 2026 | 125.00 (77.56%) | 购买 | 66.54 |
| Morgan Stanley | 25 Feb 2026 | 98.00 (39.20%) | 购买 | 66.54 |
| 06 Jan 2026 | 96.00 (36.36%) | 购买 | 73.99 | |
| Oppenheimer | 25 Feb 2026 | 81.00 (15.06%) | 购买 | 66.54 |
| 13 Feb 2026 | 83.00 (17.90%) | 购买 | 75.25 | |
| Truist Securities | 25 Feb 2026 | 95.00 (34.94%) | 购买 | 66.54 |
| 08 Jan 2026 | 86.00 (22.16%) | 购买 | 73.82 | |
| HC Wainwright & Co. | 17 Feb 2026 | 100.00 (42.05%) | 购买 | 75.85 |
| Wells Fargo | 13 Feb 2026 | 98.00 (39.20%) | 购买 | 75.25 |
| 20 Jan 2026 | 88.00 (25.00%) | 购买 | 77.19 | |
| Barclays | 28 Jan 2026 | 80.00 (13.64%) | 购买 | 77.49 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| KUMAR NEIL | - | 68.70 | -80,000 | -5,495,600 |
| VALANTINE HANNAH | - | 74.32 | -8,671 | -644,429 |
| 累积净数量 | -88,671 | |||
| 累积净值 ($) | -6,140,029 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 70.57 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| KUMAR NEIL | 职员 | 13 Mar 2026 | 自动卖出 (-) | 40,000 | 69.41 | 2,776,400 |
| KUMAR NEIL | 职员 | 12 Mar 2026 | 自动卖出 (-) | 40,000 | 67.98 | 2,719,200 |
| VALANTINE HANNAH | 董事 | 10 Mar 2026 | 自动卖出 (-) | 8,671 | 74.32 | 644,429 |
| VALANTINE HANNAH | 董事 | 10 Mar 2026 | 执行期权 | 8,671 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合